Top Markets
#1 Islamic Coin Islamic Coin +158.25%
#2 Glidr Glidr +58.56%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.53%
#4 Victoria VR Victoria VR +15.16%
#5 Cryptopia Cryptopia +9.09%
#6 Movement Movement +8.42%
#7 Pons Pons +7.64%
#8 DMT-NAT DMT-NAT +5.07%
#9 COTI COTI +5.06%
#10 MarsCoin MarsCoin +4.61%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
American Bio Medica Corporation American Bio Medica Corporation

American Bio Medica Corporation

ABMC
Rank in Stocks #42104
American Bio Medica Corporation (ABMC) specializes in the development and... American Bio Medica Corporation (ABMC) specializes in the development and distribution of lateral flow immunoassay tests, primarily designed for the rapid detection of drugs in both urine and oral fluid samples. Their extensive range of urine-based drug screening solutions includes the Rapid Drug Screen, capable of identifying between 2 and 10 substances; the RDS InCup, a convenient testing cup detecting 1 to 12 drugs; Rapid TOX, a cassette-based test for 1 to 10 drugs; and the Rapid TOX Cup II, another cup format that screens for 1 to 16 different drugs. Each product aims to swiftly determine the presence or absence of illicit substances. Furthermore, ABMC provides OralStat, an oral fluid drug test, available also in private-labeled versions. Beyond its proprietary offerings, the company acts as a distributor for various other products focused on detecting substances of abuse and identifying specific infectious diseases. The company extends its expertise to non-affiliated diagnostic firms, offering contract services that encompass the manufacturing, assembly, and packaging of diagnostic strips. Serving a diverse clientele, ABMC caters to the needs of rehabilitation and drug treatment centers, pain management clinics, general clinical settings, government agencies, and employment/workplace screening programs. Its operations span across the United States, Europe, the Asia Pacific region, and South America. Founded in 1986 as American Micro Media, Inc., the company adopted its current name, American Bio Medica Corporation, in September 1992. Its corporate headquarters are situated in Kinderhook, New York.
Share Price
$0.0001
Last synced: 2025-07-02
Market Cap
$4.81K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade American Bio Medica Corporation (ABMC)

Category

Healthcare
P/E ratio for American Bio Medica Corporation (ABMC)
P/E ratio as of 2026 TTM: 0
According to American Bio Medica Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for American Bio Medica Corporation from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 30.84 -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 34.53 -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 40.90 -
US
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 -164.27 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.